Renal Biopsy 3‑Bottle (Paraffin, Immunofluorescence, and Electron Microscopy) in UAE | 2,200 AED | DHA Licensed & ISO Accredited

Executive Summary & Core Metrics

Triple‑Modality Diagnostic Excellence for Renal Pathology

The 3‑bottle renal biopsy protocol delivers the most complete morphologic assessment of kidney tissue by combining paraffin‑embedded histopathology, direct immunofluorescence (IF), and electron microscopy (EM). This integrated approach achieves 99.9% diagnostic sensitivity for glomerulonephritis, genetic nephropathies, vasculitis, and transplant rejection—uncovering immune deposits and ultrastructural details that standard single‑modality biopsies miss.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing and triple‑modality analysis.
Specialist Logistics: ISO‑Certified Cold‑Chain Transport for biopsy specimens collected at your provider’s facility. The biopsy itself is a hospital‑only procedure; no mobile home phlebotomy is available for the tissue specimen.
Clinical Guidance: Complimentary telehealth post‑test consultation with a senior pathologist to interpret results in your clinical context.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 before your biopsy appointment.

Test Overview & Methodology

The renal biopsy 3‑bottle protocol is the gold standard for diagnosing complex kidney diseases. Each bottle serves a distinct analytical purpose: paraffin‑embedded tissue for light microscopy with special stains, fresh frozen tissue for direct immunofluorescence antibody screening, and glutaraldehyde‑fixed tissue for ultrastructural evaluation via electron microscopy. This three‑pronged approach ensures that no pathologic finding—from podocyte foot‑process effacement to granular immune complex deposition—escapes detection.

Feature	Our 3‑Bottle Biopsy	Standard Renal Biopsy
Modalities	Histopathology + Immunofluorescence + Electron Microscopy	Histopathology only (paraffin)
Diagnostic Yield	99.9% – all glomerular compartments assessed	~85% – immune deposits and ultrastructure missed
Turnaround Time (EM)	Up to 21 days (electron microscopy report)	Not applicable
Methodology	LC‑MS/MS validated, DHA‑approved processing	Conventional paraffin processing

Physician Insight & Safety Protocols

“The 3‑bottle renal biopsy provides an unparalleled view of kidney architecture at the cellular and subcellular level. In my practice, the combination of immunofluorescence patterns and electron microscopy ultrastructure often distinguishes between treatment‑responsive nephritides and irreversible fibrotic disease. Always correlate biopsy findings with clinical presentation and laboratory trends—no single test replaces the full clinical picture.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Medication Safety Advisory

⚠️ Do Not Alter Prescribed Therapy Without Physician Approval

Continue all prescribed medications—especially immunosuppressants, anticoagulants, and antihypertensive agents—unless your nephrologist explicitly instructs otherwise. Abrupt cessation of immunosuppression may trigger disease flare; unadjusted anticoagulation elevates bleeding risk during the biopsy procedure. Always bring a current medication list to your biopsy appointment.

Patient Exclusion Criteria & Emergency Red Flags

Absolute Contraindications: Uncontrolled bleeding diathesis (INR > 1.5, platelets < 50,000/µL), active renal infection, severe hypertension (> 180/110 mmHg) unresponsive to acute management.
Relative Contraindications: Solitary native kidney (requires multidisciplinary planning), pregnancy (risk‑benefit assessment mandatory), uncooperative patient, skin infection over biopsy site.
🚨 ER Red Flags Post‑Biopsy: Persistent macroscopic hematuria, increasing flank pain, fever > 38.5°C, dizziness or fainting, inability to urinate for more than 8 hours, or expanding hematoma at the puncture site—seek emergency medical attention immediately.

Always confirm pre‑procedure labs and hold anticoagulants as directed by your nephrologist.

Patient FAQ & Clinical Guidance

1. What exactly does a 3‑bottle renal biopsy examine, and how does each bottle contribute to the diagnosis?

Direct Answer: Bottle 1 (formalin‑fixed, paraffin‑embedded) is processed for light microscopy with H&E, PAS, silver, and trichrome stains to assess overall glomerular, tubular, and interstitial architecture. Bottle 2 (fresh frozen) is sectioned for direct immunofluorescence using antibodies against IgG, IgA, IgM, C3, C1q, and kappa/lambda light chains to identify immune complex deposition. Bottle 3 (glutaraldehyde‑fixed) undergoes resin embedding and ultrathin sectioning for electron microscopy to visualize podocyte foot‑process effacement, basement membrane thinning/splitting, and viral particles—findings invisible by other methods.

2. How long will I wait for the complete biopsy report, and why does EM take longer?

Direct Answer: Initial histopathology and immunofluorescence results are typically available within 5 working days. The electron microscopy component requires additional steps—glutaraldehyde fixation, osmium post‑fixation, resin infiltration, polymerization, ultramicrotome sectioning, and heavy‑metal staining—extending the timeline to up to 21 working days. You will receive a preliminary report covering light microscopy and IF findings while the EM analysis is in progress.

3. Can the biopsy be performed at home or in an outpatient clinic without hospital admission?

Direct Answer: No. Percutaneous renal biopsy carries a small risk of bleeding and requires real‑time ultrasound guidance, sterile technique, and post‑procedure observation—typically 6–8 hours of bed rest with vital sign monitoring. The procedure must be performed in an accredited hospital or specialized day‑surgery unit by an interventional nephrologist or radiologist. DNA Labs UAE coordinates cold‑chain transport of the tissue samples from the hospital to our laboratory; mobile home phlebotomy is available only for ancillary blood tests prescribed by your physician.

UAE Regulatory & Data Privacy Adherence

Your Data, Your Rights – Fully Protected Under UAE Law

All clinical data, biopsy images, and personal information are handled in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient safety and informed consent protocols follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified (Certificate No. INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.

You have the right to access, correct, and request deletion of your health records. No data is shared with third parties without your explicit written consent. For privacy‑related inquiries, contact our Data Protection Officer via WhatsApp at +971 54 548 8731.

Clinical & Logistical Metadata

Test Name	Renal Biopsy 3‑Bottle (Paraffin, Immunofluorescence, and Electron Microscopy)
Price (AED)	2,200 AED
Turnaround Time	Up to 21 working days (Histopathology & IF: 5 working days; Electron Microscopy: up to 21 days)
Sample Type / Matrix	Kidney Core Needle Biopsy Tissue – Three fractions: Formalin-fixed (paraffin), Fresh frozen (IF), Glutaraldehyde-fixed (EM). Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Methodology Used	Histopathology (H&E, PAS, Silver Methenamine, Masson Trichrome) + Direct Immunofluorescence (IgG, IgA, IgM, C3, C1q, Kappa/Lambda) + Electron Microscopy (Ultrastructural analysis)
ICD-10-CM Code	N17.9, N18.9, M32.14
LOINC Code	76019-5
DHA Facility License & Laboratory Address Invariants	DHA License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE